Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218668 · ClinicalTrials.gov registry record · Phase 2
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Woolsey Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 12
- Study locations
NCT05218668: Active Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Woolsey Pharmaceuticals.
NCT05218668 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is active but no longer recruiting, run by Woolsey Pharmaceuticals. The registered enrollment target is 40 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05218668, a Phase 2 study of Amyotrophic Lateral Sclerosis, is active but no longer recruiting, sponsored by Woolsey Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Primary Outcome
Incidence of Adverse Events (AEs\] and Serious Adverse Events (SAEs) as assessed by clinically significant abnormal physical examination findings; changes in vital signs; 12-lead electrocardiogram (ECG); magnetic resonance imaging (MRI); and hematology, blood chemistry, liver function, and urine tests.
Conditions Studied
Interventions
- DRUG Fasudil (WP-0512)
Study Locations (12)
Colorado
- University of Colorado - Aurora
- National Jewish Health - Denver
Florida
- Lakes Research - Miami Lakes
- University of South Florida - Tampa
Arizona
- Neuromuscular Research Center - Phoenix
Illinois
- Northwestern University - Chicago
Kentucky
- University of Kentucky - Lexington
Missouri
- Cox Medical Center - Springfield
New York
- Hospital for Special Surgery - New York
New South Wales
- Macquarie University Hospital - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
What the registry record for NCT05218668 still lists
NCT05218668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Fasudil (WP-0512) is the first listed.
NCT05218668 lists 12 locations in 10 states (Colorado, Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT05218668 about?
NCT05218668 is a clinical study titled "Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)". A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
What is the current status of trial NCT05218668?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-12-22. Estimated completion is 2029-01.
What conditions does trial NCT05218668 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05218668?
The interventions under investigation include: Fasudil (WP-0512) (DRUG).
Who is sponsoring clinical trial NCT05218668?
This trial is sponsored by Woolsey Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05218668 being conducted?
This trial has 12 study locations across Arizona, Colorado, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05218668's enrollment target sits among peer trials
40 58th of 102 higher than 44 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI